Physician profile
Jonathan S Tam
NPI 1619133600
$32,720.48
in general payments reported to CMS, 2019-2025
12 companies · $27K in 2025
The $27K reported for 2025 was more than what 93% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2022: $92.28 · 2023: $125 · 2024: $3,572 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $8,311 · Travel and Lodging: $2,952 · Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,600.00 |
| Consulting Fee | $8,311.42 |
| Travel and Lodging | $2,951.60 |
| Food and Beverage | $1,096.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $21,948.13 | 2025 | Neffy |
| Csl Behring | $8,670.70 | 2024-2025 | Andembry |
| Astrazeneca Uk Limited | $1,653.20 | 2019 | |
| Genentech USA, INC. | $93.21 | 2025 | Xolair |
| Regeneron Pharmaceuticals, INC. | $83.96 | 2019-2022 | |
| Dermavant Sciences, INC. | $67.25 | 2023-2024 | Vtama |
| Grifols Shared Services North America, INC. | $60.23 | 2024 | Xembify |
| Merz North America, INC. | $41.18 | 2023 | Xeomin |
| Genzyme Corporation | $38.93 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $34.04 | 2023 | |
| Glaxosmithkline, LLC. | $29.65 | 2024 | Nucala |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Tam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.